GLP-1 medications are increasingly being studied for their potential effects beyond weight loss and diabetes management. A recent study found that GLP-1 use was associated with improved breast cancer survival and lower recurrence risk among people with obesity, type 2 diabetes, or both, though experts emphasize that more research is needed to understand the connection.
According to Dr. Paunel Vukasinov, “This paper adds to growing evidence that GLP-1 receptor agonists may have an oncologic impact by improving metabolic health.” He noted that the findings should be interpreted cautiously, as the study was observational, but the results highlight the potential role of metabolic health in cancer outcomes. Read the full article here.
Would you like to schedule an appointment with Dr. Vukasinov?
